Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322148 · ClinicalTrials.gov registry record · Phase 3
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
A Phase 3 study, sponsored by Research Insight.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT05322148 is a Phase 3 study that has completed, run by Research Insight. The registered enrollment target is 59 participants.
The verdict
NCT05322148, a Phase 3 study, has completed, sponsored by Research Insight.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye
Interventions
- DRUG Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2022-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05322148
The ClinicalTrials.gov registry entry for NCT05322148 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Research Insight, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free is the first listed.
NCT05322148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05322148 about?
NCT05322148 is a clinical study titled "Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization". The CLEAN Study: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization-A Prospective Cohort Study of Combination Therapy in the Treatment of Dry Eye
What is the current status of trial NCT05322148?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2022-06-03. Estimated completion is 2022-11-21.
What interventions are being tested in trial NCT05322148?
The interventions under investigation include: Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free (DRUG).
Who is sponsoring clinical trial NCT05322148?
This trial is sponsored by Research Insight, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.